ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

From Startup ARQULE

Link to Full Article: http://investors.arqule.com/news-releases/news-release-details/arqule-present-leerink-partners-roundtable-series-rare-disease

BURLINGTON, Mass.–(BUSINESS WIRE)–Sep. 24, 2018–
ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence,
President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical
Officer and Head of Research and Development, and Marc Schegerin, Senior
Vice President, Strategy, Communication and Finance, will present at the
Leerink Partners Roundtable Series on October 2, 2018, at 8:00am ET at
the Lotte New York Palace in New York City.

The live webcast of the presentation will be available via the
“Investors & Media” section of ArQule’s website, www.arqule.com,
under “Events & Presentations.” A replay of the webcast will be
available shortly after the conclusion of the presentation.

About ArQule
ArQule is a biopharmaceutical company engaged in the research and
development of targeted therapeutics to treat cancers and rare diseases.
ArQule’s mission is to discover, develop and commercialize novel small
molecule drugs in areas of high unmet need that will dramatically extend
and improve the lives of our patients. Our clinical-stage pipeline
consists of five drug candidates, all of which are in targeted,
biomarker-defined patient populations, making ArQule a leader among
companies our size in precision medicine. ArQule’s pipeline includes:
ARQ 531, an orally bioavailable, potent and reversible inhibitor of both
wild type and C481S-mutant BTK, in Phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; Miransertib (ARQ
092), a selective inhibitor of the AKT serine/threonine kinase, in a
Phase 1/2 company-sponsored study for Overgrowth Diseases, in a Phase 1
study for ultra-rare Proteus syndrome conducted by the National
Institutes of Health (NIH), and in Phase 1b in combination with the
hormonal therapy, anastrozole, in patients with advanced endometrial
cancer; ARQ 751, a next generation AKT inhibitor, in Phase 1 for
patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase
inhibitor designed to preferentially inhibit the fibroblast growth
factor receptor (FGFR) family, in a registrational trial for iCCA; and
ARQ 761, a β-lapachone analog being evaluated as a promoter of
NQO1-mediated programmed cancer cell necrosis, in Phase 1/2 in multiple
oncology indications in partnership with the University of Texas
Southwestern Medical Center. ArQule’s current discovery efforts are
focused on the identification and development of novel kinase
inhibitors, leveraging the Company’s proprietary library of compounds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005268/en/
Source: ArQule, Inc.
Corporate Contact:ArQule, Inc.Marc Schegerin, M.D.Senior
Vice PresidentStrategy, Communication and Financeir@arqule.comwww.ArQule.comorMedia
Contact:LifeSci Public RelationsAllison Blum, Ph.D.,
646-627-8383Allison@lifescipublicrelations.com

Please visit their site for more information: ARQULE.com
All,Biotechnology,Healthcare News
2018-09-25 05:49:12